Biotech Values

[DewDiligence]

So are you saying that even though Ariad's 113 could be more potent against ALK, the cancer develops resistance through other pathways that '113 doesn't inhibit?

That’s exactly my point. A second-line ALK inhibitor may not get the job done if a patient’s resistance to Crizotinib comes from activation of other oncogenes, which is likely to be the case in many instances.